11C-胆碱PET/MR与11C-胆碱PET/CT用于生化复发前列腺癌再分期前瞻性头对头比较
94例生化复发前列腺癌患者接受单次注射、双模态显像的11C-胆碱PET/CT与PET/MR,75例纳入最终分析。PET/MR对局部复发的检出优于PET/CT,而PET/CT对淋巴结和骨转移的检出更优(PSA≤2 ng/ml亚组该差异不存在)。PET/MR辐射暴露平均降低79.7%,但显像时间明显更长。
要点
- PET/MR对局部复发的检出显著优于PET/CT,两读片组间一致性较好(K>0.6)。
- PET/CT对淋巴结和骨转移的检出显著优于PET/MR,但PSA≤2 ng/ml亚组无此差异。
- PET/MR较PET/CT辐射暴露平均降低79.7%,但平均显像时间50.4±7.9分钟明显长于18.4±0.7分钟。
核心结论
- 11C-胆碱PET/MR是生化复发前列腺癌再分期的稳健显像方法,不同读片者间判读一致。
- 与PET/CT相比,PET/MR对局部复发的诊断价值更高,并具有大幅降低辐射剂量的优势。
- PET/MR的不足是显像时间明显更长,且在PSA>2 ng/ml患者中检测骨和淋巴结转移略逊于PET/CT。
- 作者建议对低PSA值(≤2 ng/ml)患者使用11C-胆碱PET/MR,而对PSA值较高亚组则PET/CT更可取。
研究设计与样本
- 前瞻性头对头研究,94例生化复发前列腺癌患者接受单次注射/双模态显像方案:先增强PET/CT,后完全诊断性PET/MR。
- 图像由两个读片团队分别判读,评估预定区域局部复发、淋巴结和骨转移的存在,采用五分法评分。
- 以临床随访、影像和/或组织病理学作为参考标准(SOR)。
主要发现
- 75例患者符合最终图像分析条件;共188个区域判为阳性:37例局部复发、87个区域淋巴结转移、64个区域骨转移。
- 两读片团队平均检出率PET/MR为84.7%,PET/CT为77.3%(p>0.05)。
- 读片团队1中PET/MR对局部复发的识别显著多于PET/CT;两团队中PET/CT对淋巴结和骨转移的识别显著多于PET/MR。
- 在PSA值≤2 ng/ml患者亚组中,上述PET/CT与PET/MR之间的差异不存在。
- PET/MR较PET/CT辐射暴露平均降低79.7%(范围72.6-86.2%);平均显像时间PET/CT为18.4±0.7分钟,PET/MR为50.4±7.9分钟。
关键数值与推荐
- 两读片团队平均检出率:PET/MR 84.7% vs PET/CT 77.3%(p>0.05)。
- PET/MR较PET/CT辐射暴露平均降低79.7%(范围72.6-86.2%)。
- 平均显像时间:PET/CT 18.4±0.7分钟 vs PET/MR 50.4±7.9分钟。
- 几乎所有类别的模态间和观察者间一致性为中等至较高度(K>0.6)。
临床怎么用
- 作者建议对低PSA值(≤2 ng/ml)患者使用11C-胆碱PET/MR。
- 作者认为PSA值较高亚组中PET/CT更可取。
局限性
- PET/MR显像时间明显长于PET/CT(50.4±7.9分钟 vs 18.4±0.7分钟)。
- PET/MR在PSA>2 ng/ml患者中检测骨和淋巴结转移略逊于PET/CT。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Whole-body integrated 11C-choline PET/MR might provide advantages compared to 11C-choline PET/CT for restaging of prostate cancer (PC) due to the high soft-tissue contrast and the use of multiparametric MRI, especially for detection of local recurrence and bone metastases. MATERIALS AND METHODS: Ninety-four patients with recurrent PC underwent a single-injection/dual-imaging protocol with contrast-enhanced PET/CT followed by fully diagnostic PET/MR. Imaging datasets were read separately by two reader teams (team 1 and 2) assessing the presence of local recurrence, lymph node and bone metastases in predefined regions using a five-point scale. Detection rates were calculated. The diagnostic performance of PET/CT vs. PET/MR was compared using ROC analysis. Inter-observer and inter-modality variability, radiation exposure, and mean imaging time were evaluated. Clinical follow-up, imaging, and/or histopathology served as standard of reference (SOR). RESULTS: Seventy-five patients qualified for the final image analysis. A total of 188 regions were regarded as positive: local recurrence in 37 patients, 87 regions with lymph node metastases, and 64 regions with bone metastases. Mean detection rate between both readers teams for PET/MR was 84.7% compared to 77.3% for PET/CT (p > 0.05). Local recurrence was identified significantly more often in PET/MR compared to PET/CT by team 1. Lymph node and bone metastases were identified significantly more often in PET/CT compared to PET/MR by both teams. However, this difference was not present in the subgroup of patients with PSA values ≤2 ng/ml. Inter-modality and inter-observer agreement (K > 0.6) was moderate to substantial for nearly all categories. Mean reduction of radiation exposure for PET/MR compared to PET/CT was 79.7% (range, 72.6-86.2%). Mean imaging time for PET/CT was substantially lower (18.4 ± 0.7 min) compared to PET/MR (50.4 ± 7.9 min). CONCLUSIONS: 11C-choline PET/MR is a robust imaging modality for restaging biochemical recurrent PC and interpretations between different readers are consistent. It provides a higher diagnostic value for detecting local recurrence compared to PET/CT with the advantage of substantial dose reduction. Drawbacks of PET/MR are a substantially longer imaging time and a slight inferiority in detecting bone and lymph node metastases in patients with PSA values >2 ng/ml. Thus, we suggest the use of 11C-choline PET/MR especially for patients with low (≤2 ng/ml) PSA values, whereas PET/CT is preferable in the subgroup with higher PSA values.
引用
- Eiber M, Rauscher I, Souvatzoglou M, et al. Prospective head-to-head comparison of 11C-choline-PET/MR and 11C-choline-PET/CT for restaging of biochemical recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2017. PMID: 28803358. doi:10.1007/s00259-017-3797-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。